Digestive health

The IBS Prescription Menu, Sorted by Your Subtype

Save

A drug that rescues one person with IBS can flatten another, and the difference is usually subtype rather than dose or luck. This page lays out what the guidelines actually recommend on each shelf, why an antibiotic sits on the diarrhea list, and what a fair trial of any of them looks like. No doses here — those belong to the person writing the prescription.

Last updated: July 2026History

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why your subtype decides the menu

Ask what the medication for IBS is and the honest answer is that the question has no singular. The drugs are organized around what your stools do, because the physiology that makes one subtype miserable is the physiology the opposite subtype's drug would worsen. The ACG guideline is built on exactly this logic — it recommends therapy by subtype rather than by severity, with rifaximin for IBS with diarrhea and secretagogues for IBS with constipation 1.

The NIDDK names the recognized types plainly: IBS with constipation, IBS with diarrhea, and a mixed type that alternates between them 2. That IBS-C IBS-D IBS-M classification is not a filing convenience. It is the routing decision that determines which half of this page applies to you, and getting it wrong is not a neutral error — it is how someone with constipation-predominant IBS ends up on something that binds them further.

Subtype is assigned on stool form, not on symptom severity. A person with severe IBS-C and a person with severe IBS-D have almost nothing in common on a prescription pad.

Subtype is worked out from stool form on your abnormal days — the Bristol stool scale is the standard chart for this — rather than from how often you go or how much it hurts. If you have not yet run that sorting exercise, it is worth doing before an appointment rather than during one. An ibs self-assessment that arrives with two weeks of recorded stool form turns a vague consultation into a specific one.

The IBS-D shelf: slowing things down

For diarrhea-predominant IBS, the prescription options work by slowing transit, reducing urgency, or damping the signalling that drives both. The ACG guideline's headline agent here is rifaximin, a poorly absorbed antibiotic that stays largely in the gut 1. Alongside it, the guideline addresses agents that act directly on gut receptors and motility — alosetron and eluxadoline among them — as subtype-specific options for IBS-D rather than as general IBS drugs 1.

What is worth understanding about this shelf is that the agents are not interchangeable, and their trade-offs differ from one another more than their labels suggest.

  • Rifaximin is given as a defined course rather than as a daily maintenance drug, and it can be repeated if symptoms return 1. This is unusual among IBS treatments and it changes what a trial feels like: you are not signing up for something indefinite.
  • The receptor-targeted agents carry restrictions on who they suit — which is precisely why they are prescribed rather than sold over a counter, and why an honest conversation about your other conditions matters more here than on most GI drugs.
  • Loperamide, the familiar over-the-counter option, controls stool consistency but does little for pain. Many people with the ibs-d subtype discover this the hard way: the diarrhea improves and the abdomen still hurts, which is a signal to look at the pain shelf rather than to escalate this one.

The honest summary of prescription options for ibs-d is that the shelf is real, guideline-backed, and narrower than the internet implies. Most people work through it one agent at a time, in an order their clinician picks from their specific picture.

Why an antibiotic is on an IBS list at all

Rifaximin's presence on an IBS list surprises people, because IBS is not an infection. The reasoning runs through a neighbouring condition. SIBO — small intestinal bacterial overgrowth — is defined as excessive bacteria in the small bowel producing GI symptoms, and the ACG's guideline on it recommends antibiotics for symptomatic cases, though only conditionally 3.

The symptom overlap between SIBO and IBS with diarrhea is substantial, and the same drug appears on both lists. That has led to a widespread and understandable assumption: that IBS is really undiagnosed SIBO, and that a breath test would reveal it.

The guidelines do not support that leap, and the reason is worth stating rather than asserting. The ACG is explicit that breath testing for SIBO carries real limitations 3 — a test with meaningful false-positive and false-negative behavior cannot function as the arbiter of a different diagnosis. So rifaximin working for someone with IBS-D does not retroactively prove they had SIBO. A drug's effect is not a diagnosis.

SIBO is small intestinal bacterial overgrowth — excessive bacteria in a part of the gut that normally holds few. It is a defined condition with a real guideline, not a synonym for IBS.

What this means practically: rifaximin is on the IBS-D shelf on its own evidence 1, not as a SIBO treatment smuggled in. You do not need a positive breath test to be a candidate for it, and a negative one does not disqualify you.

The IBS-C shelf: drugs that bring water to the problem

For constipation-predominant IBS, the guideline-recommended prescription class is the secretagogues 1. The name describes the mechanism: rather than stimulating the bowel to squeeze harder, these agents increase the secretion of fluid into the intestine. Softer contents move more easily, and the transit problem is addressed by changing what is being moved rather than by whipping the muscle that moves it.

This is the distinction that matters most on this shelf, and it explains why a decade of stimulant laxatives may have produced cramping without resolution. The ibs-c subtype is not a strength problem.

A distinction that trips people up. IBS-C and chronic idiopathic constipation are different diagnoses that share part of a shelf. The joint AGA and ACG guideline on chronic idiopathic constipation makes strong recommendations for agents including linaclotide and lubiprostone, alongside fiber and PEG 4 — but chronic idiopathic constipation is constipation without the abdominal pain that defines IBS. The pain is the dividing line. If your constipation comes with recurrent pain tied to your bowel movements, the IBS guideline is your document; if it does not, the constipation guideline is.

Why care about a distinction that lands you on overlapping drugs? Because it decides what counts as success. Under the constipation guideline, more comfortable and more frequent bowel movements is the win. Under the IBS guideline, that result with unchanged abdominal pain is a partial response, and it points toward the pain shelf rather than toward a higher rung on this one.

People searching for prescription options when constipation won't budge are usually one conversation away from this distinction, and nobody has drawn it for them.

The drugs aimed at pain rather than at stool

There is a third shelf, and it is the one people are most surprised by: agents that treat IBS pain without targeting stool at all. The ACG guideline includes tricyclic antidepressants for global IBS symptoms, used as neuromodulators 1. The dose ranges used for this purpose are lower than those used to treat depression, and the target is the gut, not the mood — but the point here is the mechanism, not the reassurance.

IBS is a disorder of gut-brain interaction — the traffic on the nerves running between the bowel and the brain is turned up too high, so routine intestinal activity arrives as pain. A drug that turns that traffic down is treating the condition at its named mechanism. It is not treating you for imagining things, and the guideline does not place it there as a last resort for difficult patients.

Antispasmodics occupy an adjacent position — aimed at cramping rather than at transit, and generally used episodically rather than continuously.

What makes this shelf worth knowing about is a specific dead end it rescues people from. Someone whose stool has normalized on a subtype-matched drug, and whose abdomen still hurts, has often concluded that the treatment failed. It did not fail. It did its job, and the remaining symptom belongs to a different shelf. Escalating the first drug in that situation is a common and fruitless move.

Pain that persists after your stool pattern improves is not evidence that your IBS is untreatable. It is evidence that you have one symptom left and a shelf that has not been tried.

The non-drug treatments that sit on the same guideline shelf

Two things belong on this page even though neither is a prescription, because in the guideline they are not a lesser tier. The ACG recommends a limited trial of a low FODMAP diet and gut-directed psychotherapy alongside the pharmacologic options — the same document, the same weighing of evidence 1.

The diet. FODMAPs are fermentable oligosaccharides, disaccharides, monosaccharides, and polyols — a family of carbohydrates that ferment in the bowel. Monash University, where the diet originated, describes a low FODMAP approach as improving symptoms in roughly three in four people with IBS 5. Two words in the guideline's phrasing carry the weight: limited trial 1. It is a diagnostic maneuver with a reintroduction phase, not a permanent way of eating, and the restriction phase is the least important part of it.

Gut-directed hypnotherapy. A randomized trial found it produced GI-symptom improvement similar to the low FODMAP diet 6. That comparison is the useful part — not that hypnotherapy is remarkable, but that it lands in the same range as the most evidence-based dietary therapy for IBS. A single trial is not a guideline, and this is one trial. It is still enough to make the option worth naming rather than dismissing.

Both of these are slower than a prescription and neither is passive. They are on this page because a menu that lists only drugs misrepresents what the guideline actually says, and because people who exhaust the drug shelves without knowing these exist conclude, wrongly, that IBS ran out of treatments.

What a fair trial of any of these looks like

The most common way an IBS medication fails is not pharmacological. It is that the drug was never given a fair test — started in the same week as two other changes, judged against no particular target, and abandoned before anyone could say what it did. A few structural things separate a real trial from an expensive guess, and none of them require any clinical knowledge to arrange.

Change one thing. Starting a drug, a diet, and a supplement in the same week produces an uninterpretable result. If it works you will not know which one worked; if it fails you will have burned three options at once.

Decide the endpoint before you start. Which symptom is this drug supposed to fix — urgency, stool form, pain, bloating? Write it down. A drug that fixed the target and left something else is a success plus a next step, not a failure.

Keep the same diary you used for the diagnosis. Stool form, pain timing, and frequency, recorded through the trial. Recall is unreliable in both directions: bad weeks are remembered vividly and good weeks disappear.

Know the shape of the course. Some of these agents are defined courses that can be repeated 1. Others are continuous. That difference changes what week four means, and it is worth asking which kind you have been given.

Bring your subtype to the appointment. The single most useful sentence you can open with names your pattern and the evidence for it. Whether you are asking about prescription drugs for ibs-d or prescription drugs for ibs-c, the request lands differently when it arrives with two weeks of stool form behind it.

No doses appear anywhere on this page, and that is deliberate. Every agent here is titrated to a person — their other conditions, their other medications, their kidneys, their history. That calculation belongs to the clinician holding your chart, and a number printed on a health-library page is worse than no number at all.

Common questions

No. The prescription options are organized by subtype, because the mechanism that helps diarrhea-predominant IBS can worsen constipation-predominant IBS. There is a third group aimed at pain rather than at stool, which some people need in addition to a subtype-matched drug. Anyone offering a single IBS drug for everyone is describing something the guidelines do not recognize.

Rifaximin is a poorly absorbed antibiotic that stays largely in the gut, and it appears in the IBS guideline as an option for diarrhea-predominant IBS on its own evidence. It is also used for small intestinal bacterial overgrowth, which overlaps symptomatically with IBS. Being prescribed it does not mean you have been diagnosed with an infection.

Not necessarily — it may have done exactly what it targets. Stool-directed and pain-directed treatments are different shelves in the guideline. Persistent pain after stool form normalizes usually points toward the pain-directed group rather than toward a higher dose of the first drug. It is worth raising as a distinct symptom rather than as a general treatment failure.

The target is the gut. IBS is a disorder of gut-brain interaction, and the nerve traffic between bowel and brain runs too loud, so routine intestinal activity arrives as pain. Tricyclics are used as neuromodulators to quiet that traffic, at doses lower than those used in depression. The guideline places them among IBS treatments, not as a substitute for taking symptoms seriously.

Practice varies, and the guideline does not stage them as a strict sequence — a limited low FODMAP trial and pharmacologic therapy both appear as recommended options. In practice, many clinicians start with diet because it is low-risk. If a restriction trial has already been run without benefit, saying so specifically is more useful than saying diet did not help.

It depends on which shelf it is from, and the shape of the course matters: some agents are given as defined courses that can be repeated, others are continuous. The more useful move is to decide the target symptom before starting and record it. A drug judged against a vague sense of feeling better is nearly impossible to evaluate fairly.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Symptoms that come before the medication conversation

  • —Blood in or on the stool, or black tarry stool — bleeding is not an IBS symptom and is not treated with an IBS drug
  • —Weight loss you did not intend, particularly alongside a change in bowel habit
  • —Diarrhea or pain that wakes you from sleep, or fever occurring with the gut symptoms
  • —New or worsening symptoms starting from age 45 onward, or iron-deficiency anemia on a blood test

Heavy rectal bleeding, black tarry stool, or bleeding with dizziness, fainting, or a racing heart is an emergency department visit or 911, not a medication question.

This article explains how IBS medications are organized in clinical guidelines. It is general education, not medical advice, and it deliberately contains no doses. Whether any of these agents suits you depends on your other conditions and medications — a judgement only a clinician with your full history can make.

Did this answer your question?

References

  1. 1.Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B (2021). ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology. doi:10.14309/ajg.0000000000001036 ✓That IBS is treated by subtype rather than by severity, and the guideline's specific pharmacologic and psychological recommendations — rifaximin and other subtype-specific agents for IBS-D, secretagogues for IBS-C, tricyclic neuromodulators for global symptoms, gut-directed psychotherapy, and a limited trial of a low FODMAP diet.
  2. 2.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2017). Symptoms & Causes of Irritable Bowel Syndrome. NIDDK, National Institutes of Health. link ✓The recognized IBS subtypes — IBS with constipation, IBS with diarrhea, and mixed — and that symptoms vary by type.
  3. 3.Pimentel M, Saad RJ, Long MD, Rao SSC (2020). ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. American Journal of Gastroenterology. doi:10.14309/ajg.0000000000000501 ✓The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the limitations of breath-test diagnosis, and the conditional recommendation for antibiotic treatment of symptomatic SIBO.
  4. 4.Chang L, Chey WD, Imdad A, et al. (2023). American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Gastroenterology. doi:10.1053/j.gastro.2023.03.214 ✓That chronic idiopathic constipation is a separate diagnosis with its own pharmacologic guideline, including fiber, PEG, and strong recommendations for agents such as linaclotide and lubiprostone.
  5. 5.Monash University, Department of Gastroenterology (2024). About FODMAPs and IBS. Monash University (Monash FODMAP). link ✓The definition of FODMAPs as fermentable oligosaccharides, disaccharides, monosaccharides, and polyols, and that a low FODMAP diet improves symptoms in roughly three in four people with IBS.
  6. 6.Peters SL, Yao CK, Philpott H, Yelland GW, Muir JG, Gibson PR (2016). Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. doi:10.1111/apt.13706 ✓That gut-directed hypnotherapy produced GI-symptom improvement similar to the low FODMAP diet in a randomized trial — a single trial rather than guideline-level evidence.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library